EUVIMEDEUVIMED entdecken
Historischer BeitragÜbersichtsarbeitOpen Access · CC BY 4.0

Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance

Roland W Sutter, Martin Eisenhawer, Natalia A Molodecky, Harish Verma, Hiromasa Okayasu

Pathogens · 04.03.2024 · 13 (3) · 224

DOI: 10.3390/pathogens13030224 ↗

Kurz gefasst

Historischer Beitrag in der Zeitschrift Pathogens, online erschienen am 04.03.2024. Verfasst von Roland W Sutter und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tamayo Federal Solutions LLC, Virginia Beach, VA 23452, USA. Hauptthemen laut MEDLINE: Poliomyelitis, Poliovirus Vaccine, Inactivated. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inactivated poliovirus vaccine (IPV), available since 1955, became the first vaccine to be used to protect against poliomyelitis. While the immunogenicity of IPV to prevent paralytic poliomyelitis continues to be irrefutable, its requirement for strong containment (due to large quantities of live virus used in the manufacturing process), perceived lack of ability to induce intestinal mucosal immunity, high cost and increased complexity to administer compared to oral polio vaccine (OPV), have limited its use in the global efforts to eradicate poliomyelitis. In order to harvest the full potential of IPV, a program of work has been carried out by the Global Polio Eradication Initiative (GPEI) over the past two decades that has focused on: (1) increasing the scientific knowledge base of IPV; (2) translating new insights and evidence into programmatic action; (3) expanding the IPV manufacturing infrastructure for global demand; and (4) continuing to pursue an ambitious research program to develop more immunogenic and safer-to-produce vaccines. While the knowledge base of IPV continues to expand, further research and product development are necessary to ensure that the program priorities are met (e.g., non-infectious production through virus-like particles, non-transmissible vaccine inducing humoral and intestinal mucosal immunity and new methods for house-to-house administration through micro-needle patches and jet injectors), the discussions have largely moved from whether to how to use this vaccine most effectively. In this review, we summarize recent developments on expanding the science base of IPV and provide insight into policy development and the expansion of IPV manufacturing and production, and finally we provide an update on the current priorities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PoliomyelitisPoliovirus Vaccine, InactivatedHumansDisease EradicationGlobal HealthPoliovirus

Stichwörter der Autor:innen

Global Polio Eradication Initiative (GPEI)fractional-dose IPV (fIPV)inactivated poliovirus vaccine (IPV)mucosal immunity

Substanzen

Poliovirus Vaccine, Inactivated

Autor:innen und Institutionen

  • Tamayo Federal Solutions LLC, Virginia Beach, VA 23452, USA.
  • Polio Eradication Department, World Health Organization, 1211 Geneva, Switzerland.
  • Polio Surge Capacity Support Program, The Task Force for Global Health, Inc., Decatur, GE 30030, USA.
  • Division of Healthy Environments and Population, Regional Office for the Western Pacific, World Health Organization, Manila 1000, Philippines.

Förderung

  • World Health Organization

Zitieren

APA

Sutter, R. W., Eisenhawer, M., Molodecky, N. A., Verma, H., & Okayasu, H. (2024). Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance. Pathogens, 13(3), 224. https://doi.org/10.3390/pathogens13030224

Vancouver

Sutter RW, Eisenhawer M, Molodecky NA, Verma H, Okayasu H. Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance. Pathogens. 2024;13(3):224. doi:10.3390/pathogens13030224

BibTeX
@article{Sutter2024,
  author = {Sutter, Roland W and Eisenhawer, Martin and Molodecky, Natalia A and Verma, Harish and Okayasu, Hiromasa},
  title = {Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance},
  journal = {Pathogens},
  year = {2024},
  volume = {13},
  number = {3},
  pages = {224},
  doi = {10.3390/pathogens13030224}
}
Kostenlos starten →